Iberdomide - efficacy and safety in RRMM

Sagar Lonial reviews the efficacy and safety profile of iberdomide in RRMM, including key findings to date, ongoing trials, future directions, and potential clinical implications.
Lonial begins by outlining how both iberdomide and mezigdomide are novel cereblon E3 ligase modulators (CELMoDs), which bind cereblon more potently than previous agents such as lenalidomide or pomalidomide. He describes how they have been engineered to ultimately induce cell death as well as arresting cell growth, leading to a more potent immune response. Lonial goes on to review findings from early phase I trials of iberdomide in combination with dexamethasone, highlighting the improved safety profile of iberdomide compared with its predecessors.
Lonial then reviews an ongoing trial of iberdomide in RRMM and concludes that, with these trials in progress, iberdomide should soon be added to the armamentarium of new drugs that not only kill myeloma cells but also enhance the efficacy of other immune agents, including anti CD38 antibodies, bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies.